The FDA has approved ritlecitinib (LITFULO™) for patients aged 12 years and above with severe alopecia areata.
A recent study evaluated how REVIVV®could help patients with androgenetic alopecia improve their quality of life and emotional wellbeing.
A study evaluating the efficacy of diacerein 1% for epidermolysis bullosa simplex revealed it did not outperform vehicle in study endpoints.
New study maps the hidden features of inflammation in psoriatic disease, explaining the drivers behind disease severity.
Results of a Phase 3 clinical trial of guselkumab shows improvement in all minimal disease activity in adults with psoriatic arthritis.
A recent study of four patients with disabling pansclerotic morphea has revealed they share an overactive version of a protein called STAT4.
The European Commission has approved Novartis’ secukinumab (Cosentyx®) for the treatment of hidradenitis suppurativa (HS) in adults.
The FDA has approved Galderma’s Restylane Eyelight for the treatment of undereye hollows in adults aged 21 years and over.
Allergan Aesthetics, an AbbVie company, has announced that the FDA has approved their SKINVIVE™ by JUVÉDERM®.
Dermavant announces positive results from their ADORING 1 study evaluating the efficacy and safety of topical VTAMA® (tapinarof) cream, 1%.
The FDA has approved Vyjuvek (beremagene geperpavec-svdt), for the treatment of dystrophic epidermolysis bullosa (DEB).
Results from a phase 2 study of gusacitinib have demonstrated significant improvement in patients with chronic hand eczema.
The FDA has accepted the New Drug Application for investigational IDP-126 gel for the treatment of acne vulgaris.
Two phase 3 trials evaluated the use of Dupixent (dupilumab) in the treatment of prurigo nodularis in adults.
The FDA has approved Sculptra®, Galderma’s injectable poly-L-lactic acid to correct fine lines and wrinkles in the cheek area.
April W. Armstrong, MD, MPH appointed chief of the division of dermatology at University of California Health.
Tralokinumab clinical trial shows drug was well tolerated and efficacious in adolescents with moderate-to-severe atopic dermatitis (AD).
Researchers sought to understand patient perspectives relating to their experience, expectations, and preferences of psoriasis treatment.
The FDA has cleared Candesant Biomedical’s Brella™, a SweatControl Patch for the treatment of primary axillary hyperhidrosis in adults.
Arcutis Biotherapeutics has announced the FDA has accepted their NDA for roflumilast foam 0.3% for the treatment of seborrheic dermatitis.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
LiVDerm / South Beach Symposium
1801 N Military Trail, Ste 110
Boca Raton, FL, 33431
Copyright © 2025, LiVDerm. All Rights Reserved.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
